REVIEW
Add like
Add dislike
Add to saved papers

Tumors of minor salivary glands and the analysis of 106 cases.

This study is based on 106 cases of predominantly minor salivary gland tumors which were received at the University of Oklahoma College of Dentistry Department of Oral Pathology Biopsy Service from 1972 to 1995. (In this study), 55% of the cases were benign and 45% were malignant. Benign tumors include pleomorphic adenoma (68%), monomorphic adenoma (10%), oncocytoma/oncocytosis (7%), papillary cystadenoma (14%), and myoepithelioma (2%). Of the malignant tumors, 34% were mucoepidermoid carcinoma, 17% adenoid cystic carcinoma, 21% adenocarcinoma, not otherwise specified (N.O.S.), 21% polymorphous low-grade adenocarcinoma, and 6% malignant mixed tumors. There was no difference in relative incidence of benign or malignant tumors between males and females. The 7th decade was the peak occurrence age for both benign and malignant and the palate was the most frequent location.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app